Cesar D. Bautista-Sanchez , Luis E. Martínez-Bravo , Diego A. Hidalgo-Díaz
{"title":"硫唑嘌呤-阿洛嘌呤醇相互作用诱发的神经性脊髓炎视网膜频谱紊乱全血细胞减少症","authors":"Cesar D. Bautista-Sanchez , Luis E. Martínez-Bravo , Diego A. Hidalgo-Díaz","doi":"10.1016/j.nerep.2024.100219","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Azathioprine (AZA) remains a widely used treatment for neuromyelitis optica spectrum disorder (NMOSD). It heightens the risk of myelosuppression, a risk further intensified with the addition of allopurinol.</p></div><div><h3>Case presentation</h3><p>To the best of our knowledge, there have been no reported cases of this complication in NMOSD.</p></div><div><h3>Case report</h3><p>We present a 63-year-old female with NMOSD on AZA, who experienced severe myelosuppression upon initiating allopurinol. Following the discontinuation of these drugs, we prescribed granulocyte stimulants, recombinant erythropoietin, and supportive care, which resulted in hematologic improvement.</p></div><div><h3>Conclusions</h3><p>This case highlights a potential myelosuppression risk when combining AZA and allopurinol in NMOSD patients.</p></div>","PeriodicalId":100950,"journal":{"name":"Neuroimmunology Reports","volume":"6 ","pages":"Article 100219"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667257X24000202/pdfft?md5=61c35b54f2390ba44144e23ca8c6129b&pid=1-s2.0-S2667257X24000202-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Pancytopenia in neuromyelitis optica spectrum disorder induced by azathioprine-allopurinol interaction\",\"authors\":\"Cesar D. Bautista-Sanchez , Luis E. Martínez-Bravo , Diego A. Hidalgo-Díaz\",\"doi\":\"10.1016/j.nerep.2024.100219\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Azathioprine (AZA) remains a widely used treatment for neuromyelitis optica spectrum disorder (NMOSD). It heightens the risk of myelosuppression, a risk further intensified with the addition of allopurinol.</p></div><div><h3>Case presentation</h3><p>To the best of our knowledge, there have been no reported cases of this complication in NMOSD.</p></div><div><h3>Case report</h3><p>We present a 63-year-old female with NMOSD on AZA, who experienced severe myelosuppression upon initiating allopurinol. Following the discontinuation of these drugs, we prescribed granulocyte stimulants, recombinant erythropoietin, and supportive care, which resulted in hematologic improvement.</p></div><div><h3>Conclusions</h3><p>This case highlights a potential myelosuppression risk when combining AZA and allopurinol in NMOSD patients.</p></div>\",\"PeriodicalId\":100950,\"journal\":{\"name\":\"Neuroimmunology Reports\",\"volume\":\"6 \",\"pages\":\"Article 100219\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2667257X24000202/pdfft?md5=61c35b54f2390ba44144e23ca8c6129b&pid=1-s2.0-S2667257X24000202-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroimmunology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2667257X24000202\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroimmunology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667257X24000202","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pancytopenia in neuromyelitis optica spectrum disorder induced by azathioprine-allopurinol interaction
Background
Azathioprine (AZA) remains a widely used treatment for neuromyelitis optica spectrum disorder (NMOSD). It heightens the risk of myelosuppression, a risk further intensified with the addition of allopurinol.
Case presentation
To the best of our knowledge, there have been no reported cases of this complication in NMOSD.
Case report
We present a 63-year-old female with NMOSD on AZA, who experienced severe myelosuppression upon initiating allopurinol. Following the discontinuation of these drugs, we prescribed granulocyte stimulants, recombinant erythropoietin, and supportive care, which resulted in hematologic improvement.
Conclusions
This case highlights a potential myelosuppression risk when combining AZA and allopurinol in NMOSD patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
